The clinical trial included two courses of M10 CAR-T treatment. Each course included a single administration of M10 CAR-T cells and two oral doses of chidamide (30 mg each time) on Day 3 and Day 10 after M10 CAR-T infusions. M10 CAR-T cells were generated from the PBMCs isolated from haplo-identical allogeneic donors. Plasma viral load, CA HIV-1 RNA and CD4/CD8 counts were monitored at regular intervals throughout the study.
